Overview
Title
An Act To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
ELI5 AI
The "Shandra Eisenga Human Cell and Tissue Product Safety Act" is a rule that wants to teach people and doctors about the good and bad sides of using special cells and tissues for medical transplants, while also putting in place penalties if the rules aren't followed properly. It also wants to make sure everything is easy to understand and the right information is shared with everyone.
Summary AI
H. R. 7188, also known as the “Shandra Eisenga Human Cell and Tissue Product Safety Act,” aims to increase awareness about the risks and benefits of human cell and tissue transplants. It mandates the Secretary of Health and Human Services to conduct a national education campaign targeting both the public and healthcare providers. The bill also requires reviewing and potentially updating existing donor eligibility guidelines, proposes civil penalties for certain violations, and seeks to streamline the regulation of these products by providing educational resources and support to stakeholders. Additionally, it demands the publication of various statistics and updates related to the regulation of human cell and tissue products on the Food and Drug Administration's website.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The bill, titled the "Shandra Eisenga Human Cell and Tissue Product Safety Act," aims to enhance the awareness and regulatory oversight of human cell and tissue products in the United States. Mandates include a national education campaign to inform healthcare professionals and the public about the risks and benefits associated with transplants, a thorough review and potential update of existing donor eligibility guidelines, and the imposition of civil penalties for violations of regulations concerning these products. Additionally, it calls for streamlined regulatory procedures and heightened transparency through educational initiatives and public involvement.
Summary of Significant Issues
Several notable issues have been identified in the bill:
Resource Allocation and Spending: The bill lacks specific guidelines on how funds will be allocated for the educational campaign, potentially leading to inefficient use of resources.
Civil Penalties: The bill sets a significant civil penalty cap of $10 million for violations, which could be seen as excessive or lacking clear justification.
Vague Terminology: Certain sections use vague terms such as "other appropriate professionals" and "relevant aspects of donation," which could lead to misunderstandings regarding the campaign's target audience and message.
Guideline Updates: There is ambiguity in determining the criteria for updating existing guidelines, which could affect the effectiveness of regulatory improvements.
External Reference Reliance: Heavy reliance on external references, like those from the Code of Federal Regulations, without detailed explanations could lead to confusion and additional effort for stakeholders.
Administrative Burden: The requirements for workshops, educational sessions, and public feedback could lead to substantial administrative costs without clear success metrics.
Impact on the Public
The bill aims to increase public and healthcare provider awareness around the critical but complex field of human cell and tissue product transplants. By improving understanding of donation risks and benefits, it could help individuals make more informed decisions regarding organ, tissue, and eye donations. The simplification of regulatory procedures and better transparency might lead to enhanced trust in the healthcare system.
However, the bill also risks creating confusion due to its vague language and reliance on complex legal definitions. The public might face difficulties understanding the implications without explicit, user-friendly information. Additionally, the potential significant penalties for violations, while promoting compliance, could also result in increased operational costs for healthcare providers, possibly impacting service affordability.
Impact on Specific Stakeholders
Healthcare Professionals: A potential positive effect for healthcare workers could include improved access to educational resources and guidance on managing donor transplants effectively. However, ambiguity in target audience and educational content may hinder effective communication and training efforts.
Healthcare Institutions and Industry: The bill's stringent penalties for non-compliance could create significant financial risk, which could potentially drive increased diligence and compliance efforts. However, without clear guidance, institutions may face challenges determining the precise compliance requirements.
Regulatory Bodies: For regulatory agencies like the FDA, the bill offers an opportunity to enhance organizational transparency and improve regulatory processes. Yet, fulfilling these mandates can place a heavy administrative burden on these agencies, necessitating resources for workshops, public feedback, and policy updates.
Patients and Donors: Improved donor eligibility standards and streamlined regulations might increase patient and donor confidence, offering reassurance of safety and efficacy. Conversely, if the legislation fails to clearly convey its objectives and legal criteria, it could deter participation due to perceived complexity or potential risks.
Overall, while the bill presents opportunities for advancing public health and safety with regard to human cell and tissue products, its success will heavily depend on clarifying vague provisions and ensuring efficient allocation and use of resources.
Financial Assessment
The “Shandra Eisenga Human Cell and Tissue Product Safety Act” (H.R. 7188) presents several financial implications, primarily around civil penalties, yet the bill lacks explicit appropriations for educational initiatives. This commentary will explore the financial aspects of the bill, focusing on the penalties for regulatory non-compliance and the identified issues related to financial elements.
Civil Penalties
The bill introduces significant civil penalties for non-compliance with specified regulations, particularly concerning human cell and tissue products. The penalties are structured to enforce compliance:
- $20,000 for each violation, with an additional $20,000 charge for each day the violation continues after receiving notice from the Secretary.
- The total civil penalties may reach up to a maximum of $10,000,000 for violations adjudicated in a single proceeding.
These penalties aim to ensure strict adherence to the rules governing human cells and tissue products. However, one of the issues highlighted in the bill commentary is the potentially excessive or arbitrary nature of the penalty cap, which may be contentious if not adequately justified. The high limits could be seen as a deterrent against violations, but without detailed justification, there may be concerns about fairness and proportionality.
Financial Considerations and Allocations
The Act mandates the Secretary of Health and Human Services to conduct a national education campaign. Notably, the bill does not specify any direct financial allocations or designated funding for this educational effort. This lack of specificity is a point of concern, as it could lead to inefficiencies or wasteful spending without proper guidance on resource allocation. A clear budget for the campaign could prevent potential misuse of funds and ensure that the educational objectives are met effectively.
Implications of Financial References
The bill's reliance on external regulatory definitions and processes, such as the guidance updates and penalty structures, implies a broad legislative intent to leverage existing frameworks without detailing specific financial routes or measures. This reliance presents challenges, as stakeholders may need to undertake further research to comprehend the financial impacts fully.
Issues arise from the vagueness concerning expenditures related to the educational campaign mentioned in Section 3. Without defined financial allocations, implementation could encounter hurdles, both in effectiveness and accountability. Establishing explicit budgetary guidance could enhance transparency and align efforts with the anticipated outcomes.
Conclusion
In summary, while the Shandra Eisenga Human Cell and Tissue Product Safety Act outlines significant civil penalties as a financial deterrent, the lack of detailed provisions for funding the educational campaign leaves room for ambiguity and potential inefficiencies. By clearly defining financial allocations, the bill could strengthen its framework for promoting public and healthcare provider awareness while ensuring fiscal responsibility and transparency in its implementation.
Issues
The lack of clear allocation of funds in Section 3 'Human cell and tissue products transplant public awareness campaign' may lead to inefficient use of resources and potential wasteful spending.
Section 5 'Civil penalties for violation of requirements for human cell and tissue products' sets a potentially excessive or arbitrary civil penalty cap of $10,000,000, which might be controversial if not adequately justified.
The vagueness in Section 3 regarding 'other appropriate professionals' and 'relevant aspects of donation' could lead to misunderstandings or misapplications of the campaign, impacting its effectiveness.
Section 4 'Review and update of existing guidance' does not specify the criteria for determining if updating guidance is 'appropriate', potentially resulting in ambiguity and lack of accountability.
The reliance on external references in Section 2 'Definitions', without providing sufficient context, may lead to confusion and require additional effort for stakeholders to fully understand the bill.
Section 6 'Streamlining regulatory oversight of human cell and tissue products' could lead to significant expenditure through mandatory workshops and administrative tasks without clear assessment criteria for success.
In Section 4, the absence of a specific timeline for delivering a statement of explanation if guidance is not updated can lead to delays and lack of transparency.
Section 5's reliance on terms from the Code of Federal Regulations, without providing content, makes the assessment of the section's impact challenging without further research.
The terms 'minimal manipulation' and 'homologous use' in Section 6 are not defined in layman terms, potentially complicating stakeholder understanding and application.
Section 2's reliance on external definitions from the Code of Federal Regulations might necessitate deeper research for those unfamiliar, impacting the bill's accessibility.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of this act gives it the official title, which is the “Shandra Eisenga Human Cell and Tissue Product Safety Act”.
2. Definitions Read Opens in new tab
Summary AI
The section defines key terms used in the Act: “human cell and tissue product” is defined as per the Code of Federal Regulations, “Secretary” refers to the Secretary of Health and Human Services, and “Tissue Reference Group” is identified as a group within the Food and Drug Administration.
3. Human cell and tissue products transplant public awareness campaign Read Opens in new tab
Summary AI
The Secretary is tasked with creating and sharing educational materials to help health care and other professionals understand important topics about donation, like how to talk to patients and their families about donating organs, tissues, and eyes, details on screening tests for donors, and other related information.
4. Review and update of existing guidance Read Opens in new tab
Summary AI
The section mandates that the Secretary, through the Commissioner of Food and Drugs, must start reviewing existing guidelines for donor eligibility of human cell and tissue products within one year of the Act's enactment. They must consider updating specific guidance and possibly issue new recommendations within three years to reduce disease transmission risks, or otherwise explain why updates are unnecessary to the relevant Congressional committees.
5. Civil penalties for violation of requirements for human cell and tissue products Read Opens in new tab
Summary AI
The section amends the Public Health Service Act to impose civil penalties on anyone violating certain federal regulations related to human cell and tissue products. The penalties include a fine of up to $20,000 for each violation, additional daily fines for ongoing violations, and may also include an amount based on the retail value of the products involved, with a maximum total penalty of $10 million for all violations in a single case.
Money References
- Any person who, on or after the date of the enactment of the Shandra Eisenga Human Cell and Tissue Product Safety Act, violates a requirement of subparts C or D of section 1271 of title 21, Code of Federal Regulations, (or successor regulations) with respect to human cell or tissue products regulated under section 361 shall be liable to the United States for a civil penalty in an amount not to exceed the sum of— “(A)(i) $20,000 for each violation; and “(ii) in the case of a violation that continues after the Secretary provides written notice to such person, $20,000 for each subsequent day on which the violation continues; and “(B) an amount equal to the retail value of the human cell and tissue products that are the subject of the violation.
- “(2) The total civil penalty under paragraph (1) may not exceed $10,000,000 for all such violations adjudicated in a single proceeding.
6. Streamlining regulatory oversight of human cell and tissue products Read Opens in new tab
Summary AI
The section requires the Food and Drug Administration to provide educational materials and conduct workshops about human cell and tissue products, publish information on inspections and inquiries annually, and establish a public forum for discussion on the regulation of these products. By 2026, a report with recommendations for improving regulations must be submitted to Congress, taking into account factors like scientific progress and public health protection.